Cell Line Development Market is expected to reach US$ 11,161.35 Mn in 2027

by Sameer Joshi or 15-Jan-2020
Request For Sample

Report : Cell Line Development Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type (Primary Cell Line, Hybridomas, Continuous Cell Lines, and Recombinant Cell Line); By Product (Equipment and Media & Reagent); Application (Drug Discovery, Bioproduction and Tissue Engineering); and Geography

Media and reagent segment is expected to drive the growth of the global cell line development market by product

According to a new market research study of ‘Cell Line Development Market to 2027 - Global Analysis and Forecasts by Type, Product, and Application.’ The global cell line development market is anticipated to reach US$ 11,161.35 Mn in 2027 from US$ 3,694.87 Mn in 2018. The cell line development market is expected to grow with a CAGR of 13.2% from 2019-2027. The report presents trends predominating in the global cell line development market and the factors driving the market and also the factors that act as hindrances.

Regenerative medicine has the potential to replace or heal tissues as well as organs damaged by age, disease, or trauma, as well as to normalize congenital disabilities. Over the last quarter of a century, there has been an emergence of the tissue engineering industry, one that has now evolved into a broader area of regenerative medicine. Regenerative medicine is defined as a rapidly growing interdisciplinary field that involves engineering sciences to develop clinical therapies intended for maintenance, repair, replacement, and enhancement of biological function. Furthermore, the regenerative medicines using cell-based models have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, the applications mentioned above of cell line development in regenerative medicines are expected to propel the global market growth over the coming years.

The global cell line development market, based on the product, has been segmented into equipment, media, and reagent. In 2018, the media and reagent segment held the largest share of the market. Moreover, the media and reagent segment is also anticipated to register the highest CAGR in the market during the projected period.
The cell line development market majorly consists of players such as Thermo Fisher Scientific Inc., Merck KGaA, Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXi AppTec Group among others. Several companies are concentrating on inorganic strategies, such as agreement, acquisitions, and collaborations. For instance, in October 2019, Selexis SA and Teneobio, Inc. announced a commercial license agreement (CLA) for the development of Teneobio’s Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma, and prostate cancer.
The report segments the global cell line development market as follows:

Global Cell Line Development Market - By Type

  • Recombinant Cell Line
  • Hybridomas
  • Primary Cell Line
  • Continuous Cell Lines

Global Cell Line Development Market - By Product

  • Media and Reagent
  • Equipment

Global Cell Line Development Market - By Application

  • Bioproduction
  • Drug Discovery
  • Tissue Engineering

Global Cell Line Development Market - By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • U.K
    • Spain
    • Italy
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • U.A.E
    • South Africa
  • South & Central America (SCAM)
    • Brazil
    • Argentina

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@reportsweb.com